Dianthus Therapeutics报告FY结果

2024-03-22 05:16

Dianthus Therapeutics press release (NASDAQ:DNTH): Net loss for the year ended December 31, 2023 was $43.6 million or $8.45 net loss per share (basic and diluted) compared to $28.5 million or $32.57 net loss for the year ended December 31, 2022.
Research and development (R&D) expenses for the year ended December 31, 2023 were $32.8 million, inclusive of $0.9 million of stock-based compensation, compared to $29.4 million for the year ended December 31, 2022, which included $0.4 million of stock-based compensation.
$389 million of pro forma cash includes cash, cash equivalents and short-term investments as of December 31, 2023

More on Dianthus Therapeutics